Sr. Vice President, Development, Manufacturing, & Supply
Paragon Therapeutics
10/10Traction
Paragon Therapeutics engineers novel biologic drug candidates using advanced protein engineering and high-throughput screening. Their integrated CMC model accelerates the progression of these therapies from discovery to clinical trials, addressing unmet medical needs.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$483MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Developing novel biologics for complex diseases requires sophisticated protein engineering and efficient progression from discovery to clinical application. Traditional development pathways can be lengthy and resource-intensive, potentially delaying patient access to innovative therapies.
Solution
Paragon Therapeutics utilizes advanced protein engineering techniques and high-throughput screening systems to discover and optimize best-in-class biologic drug candidates. The company's proprietary CMC (Chemistry, Manufacturing, and Controls) model facilitates the rapid and reliable advancement of these novel treatments from initial concept through to clinical trials. This integrated approach allows for efficient program timelines and maintains a high standard of quality throughout the development lifecycle. Paragon's strategy focuses on creating transformative therapeutic programs designed to address significant unmet medical needs.
Target Audience
Paragon Therapeutics targets pharmaceutical and biotechnology companies seeking to license or partner on novel biologic assets, as well as investors interested in early-stage therapeutic development platforms.
Features
- Protein engineering platform for biologics discovery and optimization
- High-throughput screening systems for candidate identification
- Integrated CMC model for accelerated progression from discovery to clinical trials
- Proprietary development process focused on efficient timelines and quality assurance
- Pipeline development across multiple therapeutic areas, including immunology, inflammation, and oncology
- Formation of spin-out companies to advance specific therapeutic programs, such as Apogee Therapeutics, Spyre Therapeutics, Oruka Therapeutics, Jade Biosciences, and Crescent Biopharma